Published in the TOWNSEND LETTER for DOCTORS - JUNE 1994 pages 606 -607
View Accompanying Graph
Suppression of Frequently Recurring Herpes
Introduction: The suppression of frequently recurring herpes, by
the delivery of homeopathic medications via audio cassette technology.
A placebo-controlled double blind trial.
By Michael Kelly, President, ThoughtForms Corporation
With the invention of electroacupuncture according to Voll,
(EAV, Germany 1953), and later improvements such as the MORA-Therapy
Unit (1975); it us now possible for health care practitioners to
administer homeopathic remedies electronically.
EAV technology transfers the remedies, i.e. swallowing, or
having a substance injected into their physical body. All of this is
possible without affecting the nature of potency of the original test
set of homeopathic remedies used by the practitioner!
ThoughtForms Corporation of Minneapolis has developed a
similar patented process to transfer homeopathic remedies onto audio
cassette tapes. Just as a liquid homeopathic remedy can be produce in a
pill form, ThoughtForms Corporation has taken the liquid and produced
it in a electronic form on magnetic tapes for use by the general public
which eliminates the need for repurchasing the product at a later date
for repeated use.
Summary of A Placebo-Controlled Double Blind Trial of Michael Kelly's Audio Cassette Technology. Conducted by Donald Soli, M.D.
Twenty-six other wise healthy adults with frequently
recurring herpes, both simple-1 and simmple-2 (>6 episodes per
year). Were studied in a double blind trial comparing two audio
cassettes provided by Michael Kelly, for the suppression of recurrent
herpes infections. The patients were treated five times during the 60
days unless herpes recurred. If the patients experienced a recurrent
infection they were seen at the clinic within 24-48 hrs, examined, and
treated again with their assigned audio cassette. Twenty-three patients
completed the testing. Among the 23 evaluable patients, there were
significantly fewer recurrences (3 out of 4) in patients using the tape
K (real) than in patients using the tape M / placebo tape (8 out of 10)
The duration of therapy (60 days) was the same for all patients.
It was concluded that Michael Kelly's tape K (real tape)
suppresses simplex-1 and simplex -2 herpes in patients with frequent
Due to the limited duration of testing, it was unknown
whether the tape eliminates the latent virus in nerve ganglia i.e.
whether the infection recurs after treatment. Despite this limitation,
this study suggests that Michael Kelly's audio is useful for the
suppression of expected herpetic recurrences.
All patients studied were other wise healthy patients
between 17 and 60 years of age who had reported 6 or more recurrences
in the past year, and who agreed to abstain form using any other
medications or treatment methods, and agreed to practice effective
methods of birth control.
Mr. Kelly provided me with a tape "K" and a tape "M" . I
was further informed that one of the tapes was a placebo while the
other contained Mr. Kelly's remedies, but was not informed as tow which
was which. Both tapes contained the sound of relaxing music and the
sound of running water and were apparently identical in length.
Appearance, and sound. At the initial visit, informed consent and
medical histories were obtained, suspected lesions were examined, and
the patients were assigned to the tape "K" or the tape "M". Two coded
audio cassettes were used in the medical office with each visit by
volunteers. One cassette tape was identified as (M) and one was
identified as cassette (K). The first three consecutive days each
vounteer was tested and treated and then scheduled to return once per
month for two additional visits. During the first visit after a medical
history was taken, each person had blood drawn and then they were
tested with Voll's Dermatron, a diagnostic device that measures
electrical energy emitted by acupuncture points. After measurements
were taken all patients were instructed to listen once to the assigned
20-minute cassette with headphones. Each patient has handed the
cassette by the physician's assistant and then listened to the cassette
once per day, with each visit when they arrived in the clinic for test
in during the first three days of the study. Clinic visits were
scheduled once every 4 weeks. Additional visits were arranged as needed
to evaluate suspected recurrences within 24 hours after onset. In the
absence of a recurrence, the only treatment given every four weeks was
listening to the audio tape once every month in the medical office. The
entire test period was 60 day. We continue to monitor the patients with
monthly phone interviews regarding any changes in the frequency of
recurrences. A recurrence was diagnosed clinically when a patent
present with typical symptoms and a number of vesicles, pustules, oar
ulcers. Each patient was checked with the Voll Dermatron.
On confirmation of a recurrence (clinically) patients
immediately were tested with the Dermatron and then treated with their
assigned cassette either (K) or (M).
At the conclusion of the study, I opened an envelope that
had been provided to me by Mr. Kelly prior to the study. The letter
therein identified the "K" tape as the authentic treatment and the "M"
tape as the placebo.
Monitoring of Toxicity and Compliance
At all visits, the subjects were questioned regarding
signs or symptoms of herpetic disease, as well as any negative
reactions to the treatment. There were no complaints about negative
reactions from anyone in the (K) group. At each scheduled visit, each
patient was tested with Dermatron and each then listened to their
Viral identification was conducted with the Dermatron and
blood test were taken on the first visit and on the last visit. Due to
the late date that testing was completed, these test have not been
analyzed or reviewed.
Twenty-six patients were enrolled in the study.
Twenty-three patients completed the treatment. The data form three
patients were not included in the analysis of the results of treatment.
Two women using the treatment tape (K) withdrew from the study, and one
man using the placebo tape (M) withdrew. None of those who withdrew
reported any outbreaks of the herpes virus before discontinuing.
Effects of Treatment
Table 2 shows the outcome of treatment of the study. Significantly fewer patients (3 patients
in the tape (K) group vs. 8 in the (M) group) experienced recurrences.
The positive experiences of four patients are noteworthy.
The one woman n the (K) group who experienced a recurrence stated " I
usually have outbreaks one week after my period. Normally it takes on
week to scale over and dry up. It was amazing how it was down, a
smaller breakout, clearing and gone in three days." A man, who started
to have a recurrence on his lower lip stated, " it didn't materialize."
Another stated normally he would have had two additional recurrences by
now instead of actually experiencing none.
A third man in the (K) group experienced and outbreak the
second day the test began. He healed in two days and stated, "this is
the quickest it has ever healed." Since his infection occurred on the
second day of the test, within the first three days of the test, it was
not counted as a failure of the (K) tape. Another man in the (K) group
who did not experience any recurrence stated "in the past month I would
have normally had 2 out breaks, but nothing!"
Eleven out of 26 patients experienced recurrences. All
recurrences were confirmed with clinical visits. Of these 11, 8
patients had used the placebo tape (M), and they had a total of 10
recurrences combined. Two patients from the tape (K) had recurrences, 2
Moreover, the mean times for healing from the onset of the
first recurrence after the start of treatment were significantly
shorter in the tape (K) group. Two patients said they healed in 57%
less time (3 days instead of 7), and 50% less (3 days instead of 6),
the third one healed at his normal rat of 6 days.
In the blind study, the (K) tape treatment failed in two
of eight men and in one of three women. In the (M) group 5 women and 3
men had recurrences.
The Average Length of Recurrence
Prior to treatment, the patients reported their average duration of outbreaks as follows:
(M) Group = 11.58, 139 total days, 12 patients
(K) Group = 8.36, 92 total days, 11 patients
During treatment, the patients reported their average duration of outbreaks as follows:
(M) Group = 7.75 days, 62 total days / 8 patients 33.07% improvement
(K) Group = 4.66 days, 14 days total / 3 patients 44.25% improvement
It is believed some improvement in both groups is
attributed to the relaxing nature of the music on both tapes as well as
Additional Sample Data
Prior to test, the number of days most recent recurrence lasted:
Group (M) total 120 days, average 10
Group (K) total 98, average 8.9
The average age of the male and female participants
Men's average age = 33.34, low = 17, high = 58, total = 206
Women's average age = 28.8, low =20, high = 53, total = 173
The number of males 14, and females 12, 3 females dropped out.
Group (M) females 7, males 6, 1 female dropped out
Group (K) females 5, males 8, 2 females dropped out
Number of patients experiencing simplex-1, oral, or genital herpes, simplex-2
Group (M) 8 had simplex-1, 4 had simplex-2
Group (K) 5 had simplex-1, 2 had simplex-2 and 2 patients had both simplex 1 & 2.
None of the patients had more vesicles or reported more
severe symptoms during the treatment recurrence than they recalled
having had during their more recent pretreatment episodes.
In the (K) group there was two reports of tingling,
characteristic of incipient recurrences: however, lesions did no t
develop. After completing the treatment, all patients received copies
of the tape containing the proper sound frequencies.
Compliance was verified by visits to the medical office
and that is the only time patients had access to use the audio cassette
Two female patients moved out of state and were unable to
complete the test. Another female patient dropped out of the study
after being physically abused by her husband.
No problems, related to treatment were reported by patients with returning visits of each treatment phase.
I hereby declare that the foregoing is an accurate summary
of testing conducted under my control and supervision and that I am a
disinterested third party with respect to Michael Kelly's tape.
- Donald E. Soli, M.D. February 23, 1993
Published in the TOWNSEND LETTER for DOCTORS - JUNE 1994 pages 606 -607